US2018111982A2PendingUtilityA2

Methods, compositions and apparatuses for facilitating regeneration

59
Assignee: SIWA CORPPriority: May 23, 2008Filed: Nov 4, 2015Published: Apr 26, 2018
Est. expiryMay 23, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Lewis S. Gruber
C07K 2317/73A61K 47/48538C07K 2317/21C07K 16/18G01N 33/5091A61K 39/39533A61B 18/18A61B 18/20A61N 7/00A61B 18/1815A61B 2018/0047A61N 5/10A61N 7/02A61P 43/00A61K 47/6843A61K 47/6817A61K 39/395
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 9 . (canceled) 
     
     
         10 . A humanized antibody that binds to a glycation end-product of a cell, wherein the antibody is conjugated to a toxin. 
     
     
         11 . The antibody of  claim 10 , wherein the antibody is monoclonal. 
     
     
         12 . The antibody of  claim 10 , wherein the toxin is a toxic nanoparticle. 
     
     
         13 . The antibody of  claim 10 , wherein the toxin is a chemical toxin. 
     
     
         14 . The antibody of  claim 10 , wherein the toxin is p-aminopropionitrile. 
     
     
         15 . The antibody of  claim 10 , wherein the cell is a senescent cell. 
     
     
         16 . The antibody of  claim 10 , wherein the antibody is monoclonal,
 the toxin is a chemical toxin, and   the cell is a senescent cell.   
     
     
         17 . A composition comprising a humanized antibody that binds to a glycation end-product of a cell,
 wherein the antibody is conjugated to a toxin.   
     
     
         18 . The composition of  claim 17 , wherein the antibody is monoclonal. 
     
     
         19 . The composition of  claim 17 , wherein the toxin is a toxic nanoparticle. 
     
     
         20 . The composition of  claim 17 , wherein the toxin is a chemical toxin. 
     
     
         21 . The composition of  claim 17 , wherein the toxin is p-aminopropionitrile. 
     
     
         22 . The composition of  claim 17 , wherein the cell is a senescent cell. 
     
     
         23 . The composition of  claim 17 , wherein the antibody is monoclonal,
 the toxin is a chemical toxin, and   the cell is a senescent cell.   
     
     
         24 . A method of making an antibody-toxin conjugate, comprising:
 conjugating a toxin to a humanized antibody that binds to a glycation end-product of a cell.   
     
     
         25 . The method of  claim 24 , wherein the antibody is monoclonal. 
     
     
         26 . The method of  claim 24 , wherein the toxin is a toxic nanoparticle. 
     
     
         27 . The method of  claim 24 , wherein the toxin is a chemical toxin. 
     
     
         28 . The method of  claim 24 , wherein the cell is a senescent cell. 
     
     
         29 . The method of  claim 24 , wherein the antibody is monoclonal,
 the toxin is a chemical toxin, and   the cell is a senescent cell.

Join the waitlist — get patent alerts

Track US2018111982A2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.